SIGNATUREd18rn0p25nwr6d.cloudfront.net/CIK-0001192448/ef53f... · UNITED STATES SECURITIES AND...
Transcript of SIGNATUREd18rn0p25nwr6d.cloudfront.net/CIK-0001192448/ef53f... · UNITED STATES SECURITIES AND...
UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-KCURRENT REPORT
Pursuant to Section 13 or 15(d) ofThe Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2019
Glaukos Corporation(Exact name of registrant as specified in its charter)
Delaware 001-37463 33-0945406(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
229 Avenida Fabricante San Clemente, California
92672
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (949) 367-9600
Not Applicable(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of theregistrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of theSecurities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of thischapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct. ☐
Item 7.01. Regulation FD Disclosure.
Glaukos Corporation (the “Company”) intends to present the materials attached as Exhibit 99.1 to this Current Report onForm 8-K (the “Investor Presentation”) from time to time in presentations to investors and other stakeholders. The InvestorPresentation will also be available on the investor page of the Company’s website at http://investors.glaukos.com.
The information contained in this Item 7.01 (excluding Exhibit 99.1) shall not be deemed “filed” for purposes of theExchange Act, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing of theCompany whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits .
Exhibit No. Description99.1 Investor Presentation, dated January 2019
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to besigned on its behalf by the undersigned hereunto duly authorized.
GLAUKOS CORPORATION (Registrant)
By: /s/ Joseph E. Gilliam Name: Joseph E. Gilliam Title: Chief Financial Officer and Senior Vice
President, Corporate Development Date: January 8, 2019
Exhibit 99.1
1©2019GlaukosCorporation1January2019
2©2019GlaukosCorporationAllstatementsotherthanstatementsofhistoricalfactsincludedinthispresentationthataddressactivities,eventsordevelopmentsthatweexpect,believeoranticipatewillormayoccurinthefutureareforward-lookingstatements.Althoughwebelievethatwehaveareasonablebasisforforward-lookingstatementscontainedherein,wecautionyouthattheyarebasedoncurrentexpectationsaboutfutureeventsaffectingusandaresubjecttorisks,uncertaintiesandfactorsrelatingtoouroperationsandbusinessenvironment,allofwhicharedifficulttopredictandmanyofwhicharebeyondourcontrol,thatmaycauseouractualresultstodiffermateriallyfromthoseexpressedorimpliedbyforward-lookingstatementsinthispresentation.Thesepotentialrisksanduncertaintiesinclude,withoutlimitation,uncertaintiesaboutourabilitytomaintainprofitability;ourdependenceonthesuccessandmarketacceptanceoftheiStent®;ourabilitytoleverageoursalesandmarketinginfrastructuretoincreasemarketpenetrationandacceptancebothintheUnitedStatesandinternationallyofourproducts;ourdependenceonalimitednumberofthird-partysuppliers,someofwhicharesingle-source,forcomponentsofourproducts;theoccurrenceofacripplingaccident,naturaldisasterorotherdisruptionatourprimaryfacility,whichmaymateriallyaffectourmanufacturingcapacityandoperations;maintainingadequatecoverageorreimbursementbythird-partypayorsforproceduresusingtheiStentorotherproductsindevelopment;ourabilitytoproperlytrain,andgainacceptanceandtrustfrom,ophthalmicsurgeonsintheuseofourproducts;ourabilitytosuccessfullydevelopandcommercializeadditionalproducts;ourabilitytocompeteeffectivelyinthehighlycompetitiveandrapidlychangingmedicaldeviceindustryandagainstcurrentandfuturecompetitors(includingMIGScompetitors)thatarelargepubliccompaniesordivisionsofpubliclytradedcompaniesthathavecompetitiveadvantages;thetiming,effectandexpenseofnavigatingdifferentregulatoryapprovalprocessesaswedevelopadditionalproductsandpenetrateforeignmarkets;theimpactofanyproductliabilityclaimsagainstusandanyrelatedlitigation;theeffectoftheextensiveandincreasingfederalandstateregulationinthehealthcareindustryonusandoursuppliers;thelengthyandexpensiveclinicaltrialprocessandtheuncertaintyofoutcomesfromanyparticularclinicaltrial;ourabilitytoprotect,andtheexpenseandtime-consumingnatureofprotecting,ourintellectualpropertyagainstthirdpartiesandcompetitorsthatcoulddevelopandcommercializesimilaroridenticalproducts;theimpactofanyclaimsagainstusofinfringementormisappropriationofthirdpartyintellectualpropertyrightsandanyrelatedlitigation;andthemarket’sperceptionofourlimitedoperatinghistoryasapubliccompany.Theseandotherknownrisks,uncertaintiesandfactorsaredescribedindetailunderthecaption“RiskFactors”andelsewhereinourfilingswiththeSecuritiesandExchangeCommission,includingourAnnualReportonForm10-Kfor2017andQuarterlyReportonForm10-QforthequarterendedSeptember30,2018.OurfilingswiththeSecuritiesandExchangeCommissionareavailableintheInvestorSectionofourwebsiteatwww.glaukos.comoratwww.sec.gov.Inaddition,informationabouttherisksandbenefitsofourproductsisavailableonourwebsiteatwww.glaukos.gov.Allforward-lookingstatementsincludedinthispressreleaseareexpresslyqualifiedintheirentiretybytheforegoingcautionarystatements.Youarecautionednottoplaceunduerelianceontheforward-lookingstatementsinthispressrelease,whichspeakonlyasofthedatehereof.Wedonotundertakeanyobligationtoupdate,amendorclarifytheseforward-lookingstatementswhetherasaresultofnewinformation,futureeventsorotherwise,exceptasmayberequiredunderapplicablesecuritieslaw.Disclaimer
3©2019GlaukosCorporationWearetransformingglaucomatherapy…OURMISSIONTODAYTopioneerandleadtheglobalglaucomamarketwithmicro-scaleinjectabletherapiesthatadvancethestandard-of-careandenrichthelivesandtreatmentalternativesforglaucomapatientsworldwide.OURLONG-TERMSTRATEGICGOALToleadtheglobalophthalmicmarketforwardbybuildingrobustsustainedpharmaceutical,surgicalanddiagnosticplatformsthatprovidedrop-lessapproachesforeffectivelymanagingglaucomaandotheroculardiseases.…andtransitioningGlaukosintoanophthalmicpharma/deviceleader.OurMissionandLong-termGoal
4©2019GlaukosCorporation2013201420152016TotalNetSales(inmillions)$175-177M2018RevenueGuidance,Provided11/7/2018$138MCash&Short-TermEquivalents11Asof9/30/2018$21.0$45.6$71.7$114.4$159.320174-YrCAGR:66%86%Q32018GrossMarginWe’veMadeTremendousProgressThusFar…
5©2019GlaukosCorporationWe’veMadeTremendousProgressThusFar…KeyMetrics6/30/159/30/18%GrowthCommercialsalespersonnelworldwide65183Employeesworldwide139410195%182%iStents,iStentinjectsimplantedgloballyIssued,licensedorpendingpatents+500K+200Articlesinpeer-reviewedpublications9717CountrieswithdirectGlaukossalesoperations
6©2019GlaukosCorporation…ButWeAreJustBeginningOurLong-TermGrowthStoryNewproductsbeingevaluatedbyFDA2018revenueinvestedinR&D1429%Scientists,engineersfocusedonpipelinedevelopment30+•OptimizingworldwideClinical&Regulatorystructure•Upgradingglobalsystemsandtechnologyinfrastructure•EstablishingnewHQfacilities•Growingglobalsalesforceandmarketaccessteams•Evaluatingnewinternationalmarkets•ExpandingsizeanddepthofR&Dteams•FocusingR&Donearly-stagenewproductdevelopment,noveldrugformulationsthatleverageiDoseTMplatform•Investinginstate-of-the-arttechnicalequipment•EnhancingmanufacturingefficienciesSizeofglobalglaucomamarketserved$5B+8.2MEst.USOHT/POAGdiagnosedandtreatedeyesStrategicInvestmentstoStimulateandSupportOurGrowth1Asof9/30/2018
7©2019GlaukosCorporationMajor2018AccomplishmentsbyObjectiveObtainFDAapprovalandcommenceUScommerciallaunchofiStentinject®BeginpatientenrollmentofkeypivotalstudiesReceivediStentinjectapprovalinJune,approximatelysixmonthsfollowingPMAsubmissionExecutedpremieriStentinjectlaunchinSeptember,focusedonfacileprocedure,predictableperformanceandfavorablesafetyprofile;strongreal-worldclinicalperformancereportedInitiatedPhaseIIIstudiesforiDoseTravoprostSecuredearlyFDA510(k)IDEandinitiatedstudyforiStentinfiniteTMDriveincreasedpenetrationinourinternationalmarketsAchieved60%YoYinternationalrevenuegrowth1SecurednewregulatoryapprovalsandreimbursementinkeyinternationalmarketsExpandpharmaceuticalcapabilitiesthroughcontinuedinvestmentImplementedsignificantGlaukosPharmateamexpansionInitiatedpharmaceuticaldevelopmentagreementwithD.WesterntoexploreRho-kinase(ROCK)inhibitorsforiDosedeliverysystem1Forninemonthsended9/30/2018vs.sameperiodin2017
8©2019GlaukosCorporationNovelSurgical&PharmaceuticalGlaucomaTherapy
9©2019GlaukosCorporationOcularHypertensionIOPof21-30mmHgTargetIOP20%↓frombaseline;≤18mmHgTreatment0-1medMildOAGIOPof25-30mmHgwithminoropticnervedamageandvisualfieldlossModerateOAGIOPof>30mmHgwithmoderateopticnervedamageandvisualfieldlossAdvancedOAGUncontrolledIOPwithsignificantopticnervedamageandvisualfieldlossRefractoryOAGUncontrolledIOPwithsevereopticnervedamageandvisualfieldlossIOPismeasuredinmillimetersofmercury(mmHg).NormalIOPinhealthyeyesrangesfrom10-21mmHg.CurrentOAGTreatmentAlgorithm12345Open-AngleGlaucomaProgressionTargetIOP25%↓frombaseline;≤18mmHgTreatment~1med,laser,MIGSTargetIOP30%↓frombaseline;≤15mmHgTreatment~2meds,laser,MIGSTargetIOP35%↓frombaseline;<15mmHgTreatment~3meds,filteringsurgery,tubeshuntTargetIOP35%↓frombaseline;<15mmHg(ideally~12mmHg)Treatment3+meds,filteringsurgery,tubeshunt
10©2019GlaukosCorporationOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYAddressingfullrangeofglaucomadiseasestatesandprogressionInjectabledrugdeliveryimplant;sustaineddrugtherapyforextendedperiodsEnvisionusealoneorincombinationwithotherMIGSdevicesInjectable2-stenttherapyforstandaloneproceduresInjectable2-stenttherapyforcombo-cataractproceduresAccessessecondaryoutflowpathway;envisionuseprimarilyincombinationwithotherMIGSdevicesInjectable3-stenttherapyforstandaloneproceduresPortfolioofMicro-ScaleInjectableTherapyREFRACTORYADVANCEDMODERATEMILDOCULARHYPERTENSIONSinglestenttherapyforcombo-cataractproceduresTMTM®iStentSA,iStentSupra,iStentinfiniteandiDosearenotapprovedbytheFDA.
11©2019GlaukosCorporationOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORY2021-22201820202020-215in5:EstimatedCadenceofMajorNewUSProductIntroductionsREFRACTORYADVANCEDMODERATEMILDOCULARHYPERTENSION2023iStentSA,iStentSupra,iStentinfiniteandiDosearenotapprovedbytheFDA.AddressingfullrangeofglaucomadiseasestatesandprogressionTMTM2012®
12©2019GlaukosCorporationiStentinject:First-of-a-KindMulti-StentSystemOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYTwomulti-directional,titaniumstentspreloadedintoautoinjectionsystemDesignedtodeliveraccesstomultiplecollectorchannelsandrestorenaturaloutflowthroughtheconventionalpathwaySignificantIOPreductionacrossawiderangeofclinicalstudiesElegantandpreciseabinternoprocedure;leavesnaturalanatomyintactandsparesconjunctivaltissuePostoperativecareprofilesimilartocataractsurgery
13©2019GlaukosCorporation29Peer-ReviewedPublicationsoniStentinjectorMultipleiStent®TherapyConsecutivecaseseriesstudyinprimarilyOAGeyes;81implantedwithiStentinjectincombinationwithcataractsurgeryHengererF.Ophthalmology&TherapyDecember2018MeanIOPmmHg22.614.814.514.31216202428Preop(n=81)Year1(n=71)Year2(n=52)Year3(n=41)Reductioninmean#ofmeds68%Retrospective,single-sitecaseseriesof179eyeswithvaryingglaucomaseverityandconcomitantcataractsurgeryHarasymowycz,P.ASCRS2018MeanIOPmmHg16.213.8101418Preop6months-1yearReductioninmean#ofmeds43%7450204060PreopPostop%MedicationFreeiStentinject+CataractSurgeryiStentinject+CataractSurgery
14©2019GlaukosCorporationiStentinject:SuccessfulLaunchContinuesAmericanAcademyofOphthalmology–October2018CommerciallyavailableinUS,EU,Australia,Brazil,Canada0191Tconsistentlyreimbursed;0376add-oncoderepresentsprofessionalfeeupside
15©2019GlaukosCorporationiStentinject:RecentSurgeonObservations
16©2019GlaukosCorporationiStentinjectIvantisHydrusiStentinjectvs.CompetitionSmallestdeviceknowntobeimplantedinthehumanbody,measuring360µmx230µmPartofmarket-expandingportfoliofromMIGSpioneer
17©2019GlaukosCorporationMIGSStandaloneSolutionforAdvancedandRefractoryOAGThreeheparin-coatedtrabecularbypassstents,preloadedintoautoinjectionsystemEnhancedinsertionsystemprovidesunlimitedactivationsandsmoothimplantationofeachstentacross5-6clockhoursofSchlemm’scanalLessinvasive,fasterrecoveryandfewercomplicationsthanconventionallate-stageprocedures;noblebformationCurrentlyenrollingpatientsinclinicaltrialtosupport510(k)submissionOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYiStentinfiniteisnotapprovedbytheFDATitratableStentTherapyMeanIOPmmHg17.415.814.21014182226MeanpreopmedicatedIOPMeanpreopIOPafterwashoutMonth36-37post-washoutIOP1Stent2Stent3StentInternationalstudyofOAGpatients(n=119)withunmedicatedIOPof22-38mmHg;randomizedtoreceive1,2or3stentsinstandaloneprocedure;follow-uptocontinuefor5yearsKatzLJetalClinicalOphthalmology2018TM
18©2019GlaukosCorporationTwoheparin-coatedtitaniumstents,preloadedintoautoinjectionsystemAbilitytoentertheeyeoncetoimplantbothstentsinstraightforwardclick-and-releasemotionStandalone2-StentTherapyforMildtoModerateOAGOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYiStentSAisnotapprovedbytheFDA2StandaloneStents19.524.414.314.214.113.113.21014182226PreopBaseline(Washout)Month1Month12Month24Month36Month42International,prospectivestudy;allpatients(n=57)on1preoperativeglaucomamedication;at42months,95%ofeyesremainedmedicationfreeLindstromRASCRS2018mmHg®
19©2019GlaukosCorporationDrugReservoirScleralAnchorRetainingCapElutionMembraneTitaniumimplant(1.8mmx0.5mm)designedforcontinuousdrugdeliverydirectlyintoanteriorchamberFilledwithproprietary,novelanduber-potentformulationoftravoprost;membrane-controlledFickianelution;zero-orderratesdemonstratedinvitroandinvivoElegantandfacileinjectableprocedure;bypassingcorneaallowsformicro-elutionratestoachievetherapeuticindexAnchorkeepsdeviceinplaceandfacilitatesstraightforwardexchangeupondrugdepletionCurrentlyenrollingOHT–moderateOAGpatientsinPhaseIIIclinicaltrialsOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYiDoseTravoprost:First-of-a-KindIntraocularDrugDeliveryDeviceTMiDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluse
20©2019GlaukosCorporationiDoseTravoprostUSPhaseII:PreliminaryEfficacyResultsAverageIOPreductionsthroughMonth12rangingfrom7.9to8.5mmHgintheimplantarmsRepresents32-33%reductionintheimplantarmsAverageIOPReductionsfromBaselinethroughMonth12*FastElutionSlowElution*CalculatedusingallIOPobservationsthrougheachdatapointweightedequallymmHgTimolol0.5%8.58.48.48.28.08.07.97.97.67.67.67.66.06.57.07.58.08.59.0Week12Month6Month9Month1233%30%n=51544950534935424025242532%33%33%32%32%32%32%30%30%30%iDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluseTimololgrouprequired31%moremedicationsonaverage,comparedtoiDosecohorts
21©2019GlaukosCorporation53%iDoseTravoprost:UnderstandingNeedforAlternativetoTopicalMedicationsKeyNon-AdherenceStatistics11QuigleyHAGlaucoma:WhatEveryPatientShouldKnow2011;FriedmanDSetalInvestOphthalmolVisSci.2007;GlaucomaResearchFoundation;MarketScope2AGISInvestigatorsAmJOphthalmol.2000;LeskeMCetalArchOphthalmol.2003;BlalockSetalOphthalmology2011;OlthhoffetalOphthalmology2005KeyReasonforNon-Adherence1ComplexdosingregimensCostandforgetfulnessDifficultyinstillingdrops,especiallyforelderlypatientsAdversesideeffects(hyperemia,etc.)and/orintolerancewithtopicalmedicationsInconvenienceand/ormisunderstandingabouttheneedValueofAdherencetoTherapy2LoweringIOPisonlyprovenglaucomatreatmentLowIOPisassociatedwithreducedprogressionofopticnervedamageandvisualfielddefect,permultiplestudiesStudiesshowthatpatientswithpoormedicationadherencehaveworsevisualfielddefectseverity10-25%ofnewlyprescribedpatientsdon’trefill2ndprescription40-60%ofnewlyprescribedpatientsarestilltakingtheirmedsatendofYear170-75%rateofcompliancereportedfor“compliant”patientsPatientnon-adherencetotopicalglaucomamedicationsisubiquitous
22©2019GlaukosCorporationProstaglandinsBetaBlockersAlphaAgonistsCombinationDrugsOther53%TopicalPharmaceuticalsDominatetheMarketiDoseTravoprost:UnderstandingtheUSGlaucomaPharmaceuticalMarket201720228.2M9.8MPrimaryOAGOcularHypertensionDiagnosedandTreatedPopulationProjections(eyes)3.6%AnnualGrowth83%Surgical,includingMIGSDiagnosticsTopicalMedicationsProstaglandinAnalogsAreMostCommonFirst-LineTherapySource:MarketScopeSource:CompanyEstimates50%1Med2Meds≥3MedPatientsFrequentlyRequireMultipleMedications53%37MEst.Rxunitssold$2.2BEst.annualrevenue=
23©2019GlaukosCorporationiDoseTravoprostProcedureiDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluse
24©2019GlaukosCorporationiDoseTravoprostExchange(Removal)ProcedureiDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluse
25©2019GlaukosCorporationLeverageCoreCompetenciesLeveraginguniqueexpertiseinmicro-mechanicaldesign,assemblyandfillingprocessesBuildSeasonedTeamBuildingseasonedoculardrugdeliveryteamofchemists,scientists,engineersFocusedonearly-stageproductdevelopment,novelsustainedpharmaceuticalsystems,platformoptimizationUnderstandingdrugcharacteristicsandpredictabilityfordeliveryviaiDosesystem•Small-moleculeAPIs,highpotency,lowaqueoussolubility•Receptordoesnotlosesensitivityduringlong-termdosing•Potentialforreducedsideeffectsvs.topicaldelivery•MolecularstructurechemicallystableovertimeImplementROCKInhibitorCollaborationPreeminentROCKinhibitorresearchorganizationAbilitytoaccessDWTI’sROCKinhibitorcompoundlibraryandpotentialnewcompoundsCertainexclusiverightstodevelopnovelproductsusingcompoundsStrategyforExpandingOurMicro-ScaleRxInjectableTherapyPotential
26©2019GlaukosCorporationPotentiallyExpandingOurAnnualMarketOpportunity7x+OHT/POAGprevalence:~18Meyes8.2MeyesdiagnosedandtreatedGrowing3.5%annually33%ofstandaloneOHT/POAGpopulationispseudophakicCombinationtherapydrivesmoreopportunityforGlaukosportfolio*2017marketopportunity;basedonGlaukosalgorithmofphysicianpreferenceandcombinationtherapyutilization;assumesfullproductportfolioavailabilityforphysician2xTotalglobalopportunityUSAnnualOpportunity*(eyes)Mild-ModPOAG/Combo-cataractAdv-RefractoryPOAG/StandaloneMild-ModPOAG/StandaloneOHT-RefractoryPOAG/Standalone~0.6M~0.8M~3.8M~4.3MTotalDx&TreatedPrevalence(eyes)2.4M8.4M11.1MTotalPrevalence(eyes)2.8M17.3M21.7M
27©2019GlaukosCorporationGlaukos:TransitioningintoOphthalmicPharma/DeviceLeader•Deliveringnovelsolutionsthataddressimportantunmetclinicalneedsinlargeandgrowingmarkets•StrengtheningpositionasglobalMIGSleaderwithsuccessfulUSlaunchofiStentinject•Advancingsolidcadenceofmarket-expandingpharmaandsurgicalproductintroductionsovernext5+years•Investingstrategicallyacrossallaspectsofbusinesstostimulateandsupportlong-termgrowth•BuildingthreedistinctandcomplementarytechnologyplatformstotransformglaucomatherapySurgicalPharmaDiagnosticsDeliveringnovelglaucomatherapyacrossmultipletechnologyplatforms
28©2019GlaukosCorporation28